Free Trial

Novozymes A/S (OTCMKTS:NVZMY) Stock Crosses Below 200-Day Moving Average - Here's Why

Novozymes A/S logo with Basic Materials background
Remove Ads

Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) shares passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $60.22 and traded as low as $55.49. Novozymes A/S shares last traded at $58.72, with a volume of 9,063 shares trading hands.

Novozymes A/S Stock Down 9.1 %

The company has a market cap of $25.92 billion, a P/E ratio of 35.03, a PEG ratio of 3.87 and a beta of 0.91. The company has a 50 day moving average price of $58.18 and a 200-day moving average price of $59.96.

Novozymes A/S Increases Dividend

The company also recently declared a dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Monday, April 7th will be paid a dividend of $0.3758 per share. This is a positive change from Novozymes A/S's previous dividend of $0.17. The ex-dividend date of this dividend is Monday, April 7th. Novozymes A/S's dividend payout ratio (DPR) is presently 47.47%.

Novozymes A/S Company Profile

(Get Free Report)

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.

Featured Articles

Should You Invest $1,000 in Novozymes A/S Right Now?

Before you consider Novozymes A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.

While Novozymes A/S currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

5 International Stocks to Escape U.S. Market Volatility

5 International Stocks to Escape U.S. Market Volatility

MarketBeat’s Chris Markoch shares 5 international stock picks that could offer protection—and potential opportunity—amid the current market uncertainty.

Related Videos

3 Chip Stocks Primed for a Comeback—Have They Found the Bottom?
3 AI Stocks to Watch After NVIDIA’s Dip

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads